Hydrofarm agrees to settle $109M loan with equity

Satisfaction of the term loan is tied to the offering closing, with preferred-stock conversion and lender-warrant exercise subject to shareholder approval.

Rhea-AI Filing Summary

Hydrofarm Holdings Group, Inc. (HYFM) priced a registered direct offering of 1,599,400 common shares at $0.905 per share and a concurrent private placement of 7,611,575 unregistered common shares (or pre-funded warrants in lieu) and 9,210,975 Common Warrants. Expected gross proceeds from the combined offering are approximately $8.3 million before placement-agent fees and offering expenses. The closing is expected on or about October 27, 2026, subject to customary closing conditions.

Each Common Warrant is exercisable for one common share at $0.78 and expires five and a half years from issuance. In conjunction with the offering closing, agreements provide for satisfying the $109 million senior secured term loan in full by issuing 27.5 million shares of Series 1 Non-Voting Convertible Preferred Stock and Lender Warrants to purchase 27.5 million common shares. Each preferred share converts into one common share, and each Lender Warrant is exercisable at $0.78; conversion and exercise are subject to shareholder approval. Hydrofarm intends to use net proceeds for general corporate purposes.

Filing Explained

The filing adds a resale-registration commitment: Hydrofarm agreed to file a registration statement covering the private-placement securities and underlying shares, but those securities remain unregistered, and resales under that statement would require a prospectus.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Registered direct offering shares: 1,599,400 common shares Registered direct offering price: $0.905 per share Private-placement common shares: 7,611,575 shares +5 more

8 metrics

Registered direct offering shares 1,599,400 common shares Priced at $0.905 per share

Registered direct offering price $0.905 per share Purchase price

Private-placement common shares 7,611,575 shares Unregistered shares, or pre-funded warrants in lieu thereof

Common Warrants 9,210,975 warrants Each warrant is exercisable for one common share

Warrant exercise price $0.78 per share Common Warrants and Lender Warrants

Expected gross proceeds Approximately $8.3 million Combined offering, before placement-agent fees and offering expenses

Senior secured term loan $109 million Agreements provide for satisfaction in full in conjunction with the offering closing

Term-loan settlement securities 27.5 million preferred shares; Lender Warrants to purchase 27.5 million common shares Conversion and exercise subject to shareholder approval

Key Terms

registered direct offering, Pre-funded Warrants, Common Warrants, Series 1 Non-Voting Convertible Preferred Stock, +1 more

5 terms

registered direct offering financial

"shares of common stock in a registered direct offering"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

Pre-funded Warrants financial

"pre-funded warrants (“Pre-funded Warrants”) in lieu thereof"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

Common Warrants financial

"9,210,975 common stock purchase warrants (“Common Warrants”)"

A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.

Series 1 Non-Voting Convertible Preferred Stock financial

"27.5 million shares of Series 1 Non-Voting Convertible Preferred Stock"

at-the-market financial

"priced at-the-market under Nasdaq rules"

"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did HYFM include in its registered direct offering?

Hydrofarm agreed to sell 1,599,400 common shares in the registered direct offering at $0.905 per share. The concurrent private placement includes 7,611,575 unregistered common shares, or pre-funded warrants in lieu thereof.

How much gross proceeds does HYFM expect from the offering?

Hydrofarm expects approximately $8.3 million in gross proceeds before deducting placement-agent fees and offering expenses. The closing is expected on or about October 27, 2026, subject to customary closing conditions.

How will Hydrofarm satisfy its $109 million term loan?

In conjunction with the offering closing, agreements provide for satisfying the $109 million senior secured term loan in full by issuing 27.5 million shares of Series 1 Non-Voting Convertible Preferred Stock and Lender Warrants to purchase 27.5 million common shares. Conversion and exercise are subject to shareholder approval.

Will Hydrofarm register the private-placement securities for resale?

Hydrofarm agreed to file a registration statement covering resale of the private-placement common shares, Common Warrants, Pre-funded Warrants, and common shares underlying those warrants. Any resale under that registration statement will be made only by means of a prospectus.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/27/2026 - 09:30 AM EDT Accepted by SEC EDGAR 10/27/2026 - 09:29 AM EDT Learn about SEC filing dates

false 0001695295 0001695295 2026-10-27 2026-10-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 27, 2026

Hydrofarm Holdings Group, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39773		81-4895761
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

1510 Main Street

Shoemakersville, PA 19555

(Address of Principal Executive

Offices) (Zip Code)

Registrant’s telephone number, including area code: (707) 765-9990

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	HYFM	Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On October 27, 2026, Hydrofarm Holdings Group, Inc. (the “Company”) issued a press release announcing the pricing of a registered direct offering of shares of common stock (the “Registered Direct Offering”) and concurrent private placement (the “Private Placement” together with the Registered Direct Offering, the “Offering”) of shares of common stock, pre-funded warrants (“Pre-Funded Warrants”), and common stock purchase warrants (“Common Warrants”) and in connection with the Offering, the termination of the Company’s $109 million senior secured term loan (the “Term Loan”). A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The registered direct offering is being made pursuant to a registration statement on Form S-3 (File No. 333-291444) relating to the shares was filed with the Securities and Exchange Commission (“SEC”) on November 12, 2025 under the Securities Act of 1933, as amended (the “Securities Act”) and declared effective on December 10, 2025, the base prospectus dated December 10, 2025 thereunder and a prospectus supplement to the base prospectus to be filed with the SEC. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41^st Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.

The concurrent private placement of the common shares, Common Warrants, and Pre-funded Warrants, will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act, or Rule 506 of Regulation D promulgated thereunder. The securities offered and sold by the Company in the private placement have not been registered under the Securities Act, or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock, Common Warrants, Pre-funded Warrants, and common stock underlying the Pre-funded Warrants and Common Warrants to be issued in the private placement. Any resale of the Company’s shares under such resale registration statement will be made only by means of a prospectus.

The Company is filing as Exhibit 99.2 to this Current Report on Form 8-K portions of materials (the "Materials") that the Company may use, in whole or in part, from time to time, in meetings and other communications with investors, analysts, and other market participants. A copy of the Materials is attached to this Current Report on Form 8-K as Exhibit 99.2 and is incorporated herein by reference.

This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward Looking Statements

This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "believe," "expect," "intend," "anticipate," "plan," "will," "project," "potential" and similar expressions. They include, among others, statements regarding: the completion and timing of the closing of the Offering, and the expected gross proceeds and intended use of the net proceeds; the satisfaction and discharge of the Term Loan through the issuance to the holders of the Term Loan of Series 1 Non-Voting Convertible Preferred Stock and commons stock purchase warrants (“Lender Warrants”) to purchase Common Stock (the “Lender Warrant Shares”), and the release of related liens; the receipt of stockholder approval for the conversion of the Series 1 Non-Voting Convertible Preferred Stock and the issuance of shares upon exercise of the Lender Warrants; the filing and effectiveness of resale registration statements for the securities issued in the concurrent private placement and to the holders of the Term Loan; and the Company's future financial performance, liquidity and capital allocation plans.

These statements are based on management's current expectations and assumptions. They are subject to risks and uncertainties that could cause actual results to differ materially, including: the risk that the offering does not close when expected or at all, including because customary closing conditions are not satisfied; the risk that the conditions to the termination of the Term Loan are not satisfied on time; the risk that stockholders do not approve the conversion of the Series 1 Non-Voting Convertible Preferred Stock or the issuance of the Lender Warrant Shares, or that approval is delayed; the risk that the Company cannot file or obtain effectiveness of the required resale registration statements; the dilution to existing stockholders from the issuance of common stock, Pre-Funded Warrants, Common Warrants, Lender Warrants and Series 1 Non-Voting Convertible Preferred Stock, and from any later conversion or exercise; the impact on the market price of the common stock of future sales of shares; the risk that the Company does not regain or maintain compliance with The Nasdaq Stock Market continued listing requirements; and the other factors described under "Risk Factors" in the Company's Annual Report on Form 10-K, subsequent periodic reports, file with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update them except as required by law.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release of Hydrofarm Holdings Group, Inc. dated October 27, 2026
99.2		Investor Presentation dated October 27, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Hydrofarm Holdings Group, Inc.
Date: October 27, 2026	By:	/s/ William Toler
		Name:	William Toler
		Title:	Chief Executive Officer & Chairman of the Board of Directors
			(Principal Executive Officer)

Exhibit 99.1

Hydrofarm Holdings Group Announces Termination of $109 Million Senior Secured Term Loan in Connection with Pricing of Aggregate $8.3 Million Registered Direct Offering and Concurrent Private Placement

Shoemakersville, PA, October 27, 2026 — Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded supplies and equipment for controlled environment agriculture, today announced that it has entered into definitive agreements for the purchase of 1,599,400 shares of common stock in a registered direct offering at a purchase price of $0.905 priced at-the-market under Nasdaq rules.  In a concurrent private placement, investors also agreed to purchase 7,611,575 unregistered shares of common stock (or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof) and 9,210,975 common stock purchase warrants (“Common Warrants”) at a purchase price of $0.9050. Each Common Warrant is exercisable for one share of common stock at an exercise price of $0.78 and will expire five and a half years from the issuance date. Total gross proceeds from the offering, before deducting the placement agent fee and offering expenses are expected to be approximately $8.3 million. All of the shares of common stock, Pre-funded Warrants, and Common Warrants are being sold by the Company.

Bill Toler, the Company's Chairman and Chief Executive Officer, as well as additional officers and directors of the Company, or their respective affiliates, will participate in the offering on the same terms as the other investors.

ThinkEquity is acting as sole placement agent and advisor to Hydrofarm in connection with the transactions. The Company intends to use the net proceeds for general corporate purposes. The closing of the offering is expected to occur on or about October 27, 2026, subject to satisfaction of customary closing conditions.

In conjunction with the closing of the offering, the Company has entered into agreements with the holders of its Senior Secured Term Loan (the “Term Loan”) and the agent thereunder to issue 27.5 million shares of Series 1 Non-Voting Convertible Preferred Stock and common stock purchase warrants to purchase 27.5 million shares of common stock (“Lender Warrants”) to satisfy the Company’s Term Loan in full. Each share of Series 1 Non-Voting Convertible Preferred Stock converts into one share of common stock. Each Lender Warrant is exercisable for one share of common stock at an exercise price of $0.78. The conversion of the shares of Series 1 Non-Voting Convertible Preferred Stock and exercise of the Lender Warrants are subject to shareholder approval. 

The registered direct offering is being made pursuant to a registration statement on Form S-3 (File No. 333-291444) relating to the shares was filed with the Securities and Exchange Commission (“SEC”) on November 12, 2025 under the Securities Act of 1933, as amended (the “Securities Act”) and declared effective on December 10, 2025, the base prospectus dated December 10, 2025 thereunder and a prospectus supplement to the base prospectus to be filed with the SEC. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41^st Floor, New York, New York 10004.  The final prospectus will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.

The concurrent private placement of the common shares, Common Warrants, and Pre-funded Warrants, will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act, or Rule 506 of Regulation D promulgated thereunder. The securities offered and sold by the Company in the private placement have not been registered under the Securities Act, or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock, Common Warrants, Pre-funded Warrants, and common stock underlying the Pre-funded Warrants and Common Warrants to be issued in the private placement. Any resale of the Company’s shares under such resale registration statement will be made only by means of a prospectus.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Hydrofarm Holdings Group, Inc. 

Hydrofarm is a leading independent manufacturer and distributor of supplies and equipment for controlled environment agriculture, including plant nutrition, growing media, horticultural lighting, and climate control solutions, as well as a broad portfolio of innovative proprietary branded products. The Company manufactures its proprietary plant nutrition and growing media brands at its manufacturing center of excellence in Eugene, Oregon. For nearly 50 years, Hydrofarm has helped growers make growing easier and more productive. The Company’s mission is to empower growers, farmers and cultivators with products that enable greater quality, efficiency, consistency and speed in their grow projects.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "believe," "expect," "intend," "anticipate," "plan," "will," "project," "potential" and similar expressions. They include, among others, statements regarding: the completion and timing of the closing of the registered direct offering and concurrent private placement, and the expected gross proceeds and intended use of the net proceeds; the satisfaction and discharge of the Term Loan through the issuance to the holders of the Term Loan of Series 1 Non-Voting Convertible Preferred Stock and  Lender Warrants, and the release of related liens; the receipt of stockholder approval for the conversion of the Series 1 Non-Voting Convertible Preferred Stock and the issuance of shares upon exercise of the Lender Warrants; the filing and effectiveness of resale registration statements for the securities issued in the concurrent private placement and to the holders of the Term Loan; and the Company's future financial performance, liquidity and capital allocation plans.

These statements are based on management's current expectations and assumptions. They are subject to risks and uncertainties that could cause actual results to differ materially, including: the risk that the offering does not close when expected or at all, including because customary closing conditions are not satisfied; the risk that the conditions to the termination of the Term Loan are not satisfied on time; the risk that stockholders do not approve the conversion of the Series 1 Non-Voting Convertible Preferred Stock or the issuance of the Lender Warrant shares, or that approval is delayed; the risk that the Company cannot file or obtain effectiveness of the required resale registration statements; the dilution to existing stockholders from the issuance of common stock, Pre-Funded Warrants, Common Warrants, Lender Warrants and Series 1 Non-Voting Convertible Preferred Stock, and from any later conversion or exercise; the impact on the market price of the common stock of future sales of shares; the risk that the Company does not regain or maintain compliance with Nasdaq continued listing requirements; and the other factors described under "Risk Factors" in the Company's Annual Report on Form 10-K, subsequent periodic reports, file with the SEC. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update them except as required by law.

2

 Exhibit 99.2

Filing Exhibits & Attachments

6 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 11.9 KB
• EX-99.2 EXHIBIT 99.2 1.7 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 11.2 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 15.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.3 KB